The tumor suppressor gene product BRCA1 is a component of the RNA polymerase II (pol II) holoenzyme that is involved, through binding to various regulatory proteins, in either activation or repression of transcription. Using a yeast two-hybrid screen, we have identified a human zinc-finger-containing protein NUFIP that interacts with BRCA1. The ubiquitous, stably expressed, nuclear protein NUFIP specifically stimulates activatorindependent pol II transcription in vitro and in vivo. Immunodepletion of the endogenous NUFIP causes a marked decrease of pol II transcription, which is then shown to be restored by stable complex of ectopically produced NUFIP and associated factors. NUFIP not only interacts with BRCA1 but also associates with the positive elongation factor P-TEFb through interaction with the regulatory Cyclin T1 subunit. Cyclin T1 is required for BRCA1-and NUFIP-dependent synergistic activation of pol II transcription in 293 cells. Mutation of the zincfinger domain abolishes the NUFIP-mediated transcriptional activation. We show that NUFIP is associated with preinitiation complexes, open transcription complexes, and elongation complexes. In addition, NUFIP facilitates ATP-dependent dissociation of hyperphosphorylated pol II from open transcription complexes in vitro.
Introduction
BRCA1, a tumor suppressor protein specific for breast and ovarian cancers, has been implicated in regulating the nuclear processes of repair of damaged DNA, chromatin remodeling, ubiquitination, and transcription (reviewed in Chen et al., 1999; Monteiro, 2000; Venkitaraman, 2001; Starita and Parvin, 2003) . Cells deficient in BRCA1 have defects in transcriptioncoupled repair, homologous recombination, nonhomologous end-joining, and microhomology end-joining (Abbott et al., 1999; Moynahan et al., 1999; Zhong et al., 2002a, b) . Emerging evidence indicates that BRCA1 undergoes phosphorylation by several checkpoint kinases (Cortez et al., 1999; Tibbetts et al., 2000; Gatei et al., 2001) , and these modifications are required for sensing or signaling of DNA damage. BRCA1, present in the sites of DNA double-strand breaks, is presumed to interact with either RAD50-MRE11-NBS1 complex or RAD51 to stimulate the repair of the lesions (Scully et al., 1997b; Zhong et al., 1999; Paull et al., 2001) . Among many critical pathways, BRCA1 regulates the transcription of DNA-damage-responsive genes p21
WAF1/CiP1 and GADD45 (Harkin et al., 1999; Li et al., 1999) . Importantly, BRCA1 co-purifies with the RNA polymerase II (pol II) holoenzyme (Scully et al., 1997a) , and this association is partly mediated by RNA helicase A, a component of pol II holoenzyme complex (Anderson et al., 1998) . BRCA1 was also shown to contact the pol II holoenzyme components RPB2 and RPB10a (Schlegel et al., 2000) , p300/CBP (Pao et al., 2000) , and BARD1 (Chiba and Parvin, 2002) . BRCA1 and BARD1 together repress the polyadenylation of mRNA transcripts following DNA damage (Kleiman and Manley, 2001) . Further, BRCA1 can activate transcription in vitro (Haile and Parvin, 1999) , and in transiently transfected cells, for example, as a p53 coactivator (Ouchi et al., 1998; Somasundaram et al., 1999) or as a chromatin remodeling agent (Hu et al., 1999) . It has been shown to associate with factors that control chromatin structure, SWI/SNF and histone deacetylases HDAC1 and HDAC2 (Bochar et al., 2000; Yarden and Brody, 1999) . BRCA1 binds to DNA with high affinity, but in a sequence-nonspecific fashion. However, BRCA1 can also interact with other DNA-binding proteins (see Deng and Brodie, 2000 , and the above reviews). The significance of these interactions is as yet unclear, but they provide further evidence of a role for BRCA1 in transcription and suggest that this protein can behave as a positive or negative regulator in different contexts. The issue of whether BRCA1 acts as a 'true' transcription factor or a coactivator remains open. Several laboratories have undertaken a global two-hybrid approach to identify BRCA1-interacting proteins in both yeast and mammalian systems. Using a yeast two-hybrid screen, BRCA1 was shown to interact with COBRA1, a subunit of the negative elongation factor NELF (Ye et al., 2001; Narita et al., 2003) . A complex of NELF and DSIF (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole sensitivity-inducing factor) constitutes the complete activity termed N-TEF (Yamaguchi et al., 1999a, b) , which is involved in negative regulation of transcription elongation by pol II before the action of positive elongation factor b (P-TEFb) (Price, 2000) . Recently, different P-TEFb complexes have been identified. These heterodimers contain a catalytic subunit cyclin-dependent kinase (cdk) cdk9 and one of the regulatory subunits Cyclin T1, T2, or K (Wei et al., 1998; Peng et al., 1998; Fu et al., 1999) . Two isoforms of cdk9 exist in cells, cdk9(42) and 13-kDa larger cdk9(55) (Shore et al., 2003) . T1 is the major form of the cyclin and shares extensive sequence similarity with CycT2 and CycK in its cyclin box at the N-terminus, which contains the cdk9 binding domain. In contrast to CycK, which is the smallest cyclin in the P-TEFb group due to its short C-terminal domain (CTD), CycT1 and CycT2 contain long C-terminal extensions. The histidine-rich stretch in the CTD of CycT1 binds the unphosphorylated CTD of pol II (Taube et al., 2002) . P-TEFb is a component of the preinitiation complex (PIC) (Ping and Rana, 1999) and its kinase subunit cdk9 phosphorylates the CTD, which then enhances processivity of pol II to produce fulllength RNAs (Marshall and Price, 1995; Marshall et al., 1996) . In addition to the CTD, P-TEFb phosphorylates DSIF to overcome N-TEF-dependent arrest and release pol II for elongation (Ivanov et al., 2000; Kim and Sharp, 2001) .
In this study, we used the yeast two-hybrid approach in an attempt to identify additional BRCA1-interacting protein(s), possibly involved in transcriptional regulation. The search resulted in the identification of a protein of 495-amino-acid residues that has also been found to interact, through the Cyclin T1 subunit, with whole P-TEFb. This protein is identical to nuclear fragile X mental retardation protein (FMRP) interacting protein (NUFIP) (Bardoni et al., 1999) . In addition to a proline-rich stretch at its N-terminus (amino acids 18-109), NUFIP also contains a bipartite nuclear localization sequence at positions 243-260, a putative C 2 H 2 -type zinc-finger motif at positions 174-201, and a cdk site at positions 292-295. Our results indicate that this nuclear protein is constantly expressed through the cell cycle in different cells. NUFIP can function as a pol II-specific basal transcriptional activator in vitro and when ectopically overexpressed in vivo. We find that the intact zinc-finger domain is required for gene stimulation. The maximum NUFIP stimulation activity can be achieved in the context of transiently coexpressed BRCA1 and Cyclin T1. Using the immobilized DNA template assay, we show that NUFIP is associated with the template throughout the transcription cycle. In addition, we found that NUFIP enhances the ATP-dependent release of hyperphosphorylated form of pol II from open transcription complexes. This suggests that NUFIP can act directly at activated promoters.
Results

NUFIP is an abundant ubiquitous nuclear protein that interacts with BRCA1
We screened a human B-lymphocyte cDNA library for genes encoding BRCA1-interacting proteins using a yeast two-hybrid system (see Materials and methods). One of the clones pulled out contained a 1.6 kb insert with a putative protein-coding region followed by a long untranslated region. To isolate the full-length cDNA clone, the original 1.6 kb cDNA was labeled by random priming and used in a second screen of the same human B-lymphocyte cDNA library. Sequence analysis of the longest cDNA revealed an open reading frame of 495 amino acids (Figure 2a) . A computer-assisted homology search of GenBankt at the National Center for Biotechnology Information found that the resulting open reading frame differs from that predicted by an entry (accession number AF159548) by a single nucleotide change at position 1434. Since this nucleotide change is in a silent position, the predicted amino-acid sequence is identical to FMRP-interacting protein (NUFIP) (Bardoni et al., 1999) . To facilitate the study of the interaction between NUFIP and BRCA1, antibodies specific to NUFIP were prepared by using GST-NUFIP fusion protein as an antigen for immunizing mice. As shown in Figure 1A , the anti-NUFIP antibody immunoreacts with a single protein corresponding to a molecular weight of 70 kDa in T24 whole-cell lysate, as well as rabbit reticulocyte lysate programmed with a NUFIP expression construct ( Figure 1A , lanes 1 and 2), but not with an empty expression vector ( Figure 1A , lane 3) as expected. Using this antibody, we examined whether NUFIP interacts with BRCA1 in human cells. The nuclear extract prepared from untransfected HeLa cells was prepared and used for a co-immunoprecipitation (Co-IP) assay with protein A-sepharose beads coupled with anti-NUFIP antibody. The immunoprecipitates were analysed by a Western blot assay using anti-BRCA1 antibody. Endogenous BRCA1 was detected in the immunoprecipitated material obtained by anti-NUFIP antibody but not in the material retained by preimmune IgG ( Figure 1B , a, lanes 3 and 2). This interaction was confirmed in a reciprocal experiment where endogenous NUFIP was brought down by anti-BRCA1 antibody ( Figure 1B , b, compare lane 3 with control lane 2). We then studied the interaction of NUFIP with the N-terminal part of BRCA1 in an in vitro GST pull-down assay. The recombinant NUFIP, expressed in reticulocyte lysate, was mixed with GST alone and GST fusion of the BRCA1 amino acids 1-303 that had been prebound to glutathione-agarose beads. To avoid nonspecific protein-DNA-protein interactions bridged by plasmid DNA, ethidium bromide was included in the reactions. Figure 1B shows that NUFIP was selectively retained by immobilized GST-BRCA1(1-303) ( Figure 1B , c, lane 3) but not GST alone ( Figure 1B , c, lane 2).
Although the calculated molecular weight of NUFIP was determined to be 56.38 kDa, the slower mobility upon sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) might be due to the prevalence of strongly basic amino acids (77 K þ R) over strongly acidic amino acids (62 D þ E), resulting in a total positive charge of the NUFIP molecule (pI 9.2).
NUFIP has been found to be expressed at a similar level in a variety of different cell types, including multiple benign as well as malignant cell lines, and protein expression remains constant through the cell cycle (unpublished results). An indirect immunofluorescence staining confirmed that endogenous NUFIP exhibits a fine speckled nucleoplasmic pattern (Bardoni et al., 2003) with a minimal labeling in the nucleolus and the cytoplasm (data not shown).
Together, these data indicate that BRCA1-interacting protein NUFIP is a relatively abundant nuclear protein without apparent cell or tissue specificity.
NUFIP and BRCA1 are required for efficient transcription from AdML promoter
To investigate whether NUFIP, besides of BRCA1, plays any role in transcription, we used beads coated with anti-NUFIP and anti-BRCA1 antibodies to deplete HeLa nuclear extracts of endogenous NUFIP and BRCA1, respectively. The extracts were then tested for antibodies. Aliquots of the variously treated extracts were then tested for their ability to direct transcription from the AdML promoter. The unit amount of each antibody is indicated above the lanes. Lane 5 shows the transcription activity of untreated nuclear extract. Correctly initiated RNA transcripts are indicated at the right. (D) HeLa nuclear extract was treated with beads carrying equal amounts of anti-NUFIP and anti-BRCA1 antibodies (lanes 2-12). The following eluates purified from 293 cells that express HA-NUFIP or HA-BRCA1 (see Materials and methods) were added to the depleted extract and tested for MLP transcription: none (lane 2); 1, 2.5, or 5 ml of HA-NUFIP (lanes 3, 4, and 5, respectively); 1, 2.5, or 5 ml of HA-BRCA1 (lanes 6, 7, and 8, respectively); 1 or 2.5 ml of each HA-NUFIP and HA-BRCA1 (lanes 11 and 12, respectively). As controls, lanes 9 and 10 show the same depleted extract complemented with 2.5 or 5 ml of eluate purified from nontransfected 293 cells, and lane 1 shows MLP transcription in nuclear extract treated with beads coated with preimmune IgG. The MLP-derived transcripts are indicated at the right Transcriptional activation by BRCA1/NUFIP/P-TEFb P Čabart et al their ability to support transcription from adenovirus major late promoter (AdMLP), a typical mRNA-type pol II gene promoter. The results are shown in Figure 1C . As a control, we treated the extract with preimmune IgG beads, which resulted in a little effect on transcription ( Figure 1C , see lanes 1 and 5) as expected.
A slight loss of transcription activity of nuclear extract is likely due to an overnight treatment at 41C. Importantly, treatment of the extracts with affinity-purified anti-NUFIP antibody significantly reduced AdML gene transcription ( Figure 1C , lane 2). Consistent with the published results on co-immunopurification of BRCA1 and pol II transcription activity (Scully et al., 1997a; Krum et al., 2003) , depletion of BRCA1 inhibited transcription as well ( Figure 1C , lane 3). Moreover, codepletion of BRCA1 and NUFIP, with the same total amount of antibodies as used for individual immunodepletions, severely debilitated the transcription signal ( Figure 1C , lane 4). To ensure that these inhibiting effects resulted from depletion of NUFIP and BRCA1, we tested whether added recombinant NUFIP and BRCA1 could reconstitute transcription in the depleted extracts. It has been reported that BRCA1 can be captured in close association with a set of vital components of the cellular transcription machinery (see Introduction). Because modification of endogenous NUFIP or stable association with other transcription factors could also be required for recovery of transcription, we used 293 cell lines that express epitope-tagged HA-NUFIP and HA-BRCA1 proteins. The protein preparations specifically eluted with HA peptide were then added to the extracts treated with both anti-NUFIP and anti-BRCA1 antibodies. As shown in Figure 1D , addition of increasing amounts of HA-NUFIP or HA-BRCA1 eluates to the double-treated extracts partially restored transcription ( Figure 1D , lanes 3, 4 and lanes 6, 7, respectively). The efficiency of AdMLP transcription was not greatly affected by further increasing the amount of HA-BRCA1 ( Figure 1D, lane 8) , and the presence of the highest amount of HA-NUFIP resulted in a dramatic loss of detectable pol II activity ( Figure 1D , lane 5). These data suggest that the lower amounts of either proteins were already saturating relative to the amounts of the other factors that remained in treated extracts and that an excess of NUFIP can inhibit transcription per se. A preparation from a control cell line was found to have no effect on this system ( Figure 1D , lanes 9 and 10). When we complemented extracts with both HA-NUFIP and HA-BRCA1, transcription was reconstituted to the level comparable to that in the preimmune IgG-treated extract ( Figure 1D , cf. lane 12 with lane 1). We next tested whether bacterially expressed and affinity purified recombinant NUFIP is able to restore MLP transcription activity in extract that had been depleted of NUFIP. By contrast, NUFIP alone was not able to restore this transcription system (data not shown), perhaps due to simultaneous removal of BRCA1 and associated factors and/or as yet unidentified NUFIPinteracting regulator.
These results confirm the requirement of BRCA1 for pol II transcription and suggest that NUFIP, as a component of larger multiprotein complex, is also involved in transcription.
NUFIP stimulates pol II, but not pol I and pol III, promoters in 293 cells
Given that the NUFIP is required for pol II transcription in vitro, we analysed the possible effect of overexpression of NUFIP on cellular transcription. BRCA1 has been shown to activate or repress various pol II promoters (reviewed in Chen et al., 1999; Monteiro, 2000; Parvin, 2001 ). However, BRCA1 contacts RPB10a (Schlegel et al., 2000) , which is a common component of all three RNA polymerases. Thus, the possibility that BRCA1 and its interacting proteins might also regulate pol I and pol III transcription cannot be excluded. To test the effect of NUFIP on pol II and III transcription, increasing amounts of construct expressing full-length NUFIP driven by cytomegalovirus (CMV) promoter (pNUFIP-wt) were transfected into 293 cells along with the SV40-b-galactosidase gene that is transcribed by pol II. In addition, 7SK and Ad2 VA1 pol III-specific constructs (representing pol III genes with gene external and internal promoter Transcriptional activation by BRCA1/NUFIP/P-TEFb P Čabart et al sequences, respectively) were cotransfected. A widerange titration experiment resulted in a very little modulation of 7SK and VA1 transcription (not shown). Therefore, the data for b-galactosidase activity were normalized to the corresponding 7SK and VA1 values that were used as transfection efficiency controls ( Figure 2B ). Addition of 1 and 2.5 mg of pNUFIP-wt resulted in an approximately twofold and fourfold increase of b-gal expression, respectively, relative to pcDNA3 alone. At higher concentrations of cotransfected DNA (5, 7.5, and 10 mg), we observed no effect or even inhibition of transcription. Overexpressed NUFIP was also capable of activating the SV40-b-gal reporter in HeLa cells, suggesting its effect on pol II transcription is not cell specific (data not shown).
Transcription of a pol I-transcribed pseudo-wild-type ribosomal gene was unaffected by transfection of the NUFIP expression vector (unpublished observations).
These results indicate that transcription by pol II is specifically modulated by NUFIP, while transcription by pol I and pol III is not. Since BRCA1 is linked to the pol II holoenzyme (Scully et al., 1997a; Anderson et al., 1998) and NUFIP interacts with BRCA1, the NUFIPmediated activation of a pol II reporter gene may be due to a direct interaction between NUFIP and the pol II transcription apparatus.
Intact zinc-finger domain is required for activation of SV40 promoter by NUFIP
To investigate the functional importance of the zincfinger motif, a pNUFIP-wt derived mutant construct (pNUFIP-Zn À ) was cotransfected. It encodes a fulllength NUFIP protein bearing double amino-acid substitution, His to Gly at position 196 and Cys to Gly at position 199 within the 28-amino-acid zinc-finger domain ( Figure 2A ). In addition to the conserved second histidine (position 196) , the cysteine at position 199 was also mutated to support a possibility that the structural integrity of the zinc-finger is disrupted. In comparison to pNUFIP-wt, the titration of the same plasmid concentrations (1-10 mg) resulted in no stimulation of b-gal activity by NUFIP-Zn À overexpression ( Figure 2B ). A number of experimental reports have demonstrated the DNA-or RNA-binding property of some zinc-finger proteins that belong to the C 2 H 2 domain family. However, NUFIP-Zn À retained its low nonspecific DNA-binding affinity (data not shown). This result is in line with the report of Bardoni et al. (1999) , who found that mouse NUFIP bearing mutated zinc-finger can still bind RNA. Hence, a mechanism of the involvement of the zinc-finger in transcription activation remains to be determined.
NUFIP-mediated stimulation of activator-independent AdML gene transcription in vitro
Having established a specific positive effect of NUFIP on pol II-directed transcription in vitro and in vivo, we next studied its activity in a reconstituted basal transcription assay using the modified AdDMLP gene.
This plasmid template lacks activator-binding sequences upstream from position À53 including USF-binding sites (Sawadogo and Roeder, 1985) with the core promoter sequences fused with the G-less cassette at position þ 10 ( Buratowski et al., 1988) (Figure 3C, PT) . Therefore, we first tested various amounts of 293 nuclear extract for the ability to support a minimal level of DMLP transcription ( Figure 3B, lanes 1-4) . The lowest amount of nuclear extract (2 mg) that still gives a detectable signal ( Figure 3B, lane 4) was then preincubated with Escherichia coli-expressed GST-NUFIP and GST alone and transcription initiated with an addition of template and nucleotides ( Figure 3A ). As shown in Figure 3B , increasing amounts of GST-NUFIP significantly increased basal transcription of the DML gene ( Figure 3B, lanes 10-12) . Consistent with the experiment shown in Figure 1C , b (lane 5), a typical squelching P]UTP, and DMLP plasmid template (0.5 mg) were added and transcription was allowed to proceed for 60 min at 301C. (B) Lanes 1-4 show transcription supported by 10, 6, 4, and 2 mg of untreated NE. A measure of 2 mg of NE was treated with 10, 30, 100, or 300 ng of GST (lanes 6, 7, 8, and 9, respectively) or 10, 30, 100, or 300 ng of GST-NUFIP (lanes 10, 11, 12, and 13, respectively) as depicted in panel A. Lane 5 shows nuclear extract treated with transcription buffer. The transcripts initiated from the DML promoter are indicated at the left. The transcription values (showed underneath) are expressed as a percentage of the signal generated by 10 mg of nuclear extract. (C) Schematic representation of the DMLP plasmid (PT) and immobilized (IT) transcription templates. The numbering indicates the distances from the transcription start site, and the direction of pol II transcription is indicated below the promoter structure. Downstream of þ 10, a G-less sequence cassette is included. A linear DNA fragment comprising sequences between À53 and þ 210 is immobilized on streptavidin-coated magnetic beads (MB) at its 3 0 end (IT)
Transcriptional activation by BRCA1/NUFIP/P-TEFb P Čabart et al effect was observed at the highest GST-NUFIP concentration used ( Figure 3B , lane 13). In comparison to untreated nuclear extract, 2 mg of nuclear proteins exposed to 301C for 15 min exhibited a loss of detectable transcription activity ( Figure 3B , cf. lanes 4 and 5) that might evoke a nonspecific protective effect of the added recombinant proteins on transcription factors. However, equivalent amounts of the GST control protein had no effect ( Figure 3B , lanes 6-9), indicating that activation by GST-NUFIP is specific. It is important to note that the assay was performed with extract that was not depleted of any cellular protein. Thus, the bacterially expressed NUFIP came out to be sufficient to activate this transcription. In summary, the data suggest that NUFIP activates both in vivo and in vitro transcription from at least two different pol II-specific promoters. Furthermore, this activation is presumably independent of upstream enhancers.
NUFIP is a component of AdDMLP PICs and remains associated with elongation complexes
To investigate the mechanisms of transcriptional activation by NUFIP, we used an immobilized template system (Arias and Dynan, 1989) . This approach allowed us to monitor the fate of endogenous NUFIP during PIC formation, isomerization of the PIC from closed to open complex, and elongation. Linear AdDML promoter DNA was immobilized on magnetic beads at the 3 0 end ( Figure 3C , IT). HeLa nuclear extract was incubated with the immobilized template to allow PIC formation, the template was washed with transcription buffer to remove unbound proteins, and ATP or NTPs added ( Figure 4A ). At the end of the reaction, the template-bound proteins were separated from the beads and selected proteins were analysed by Western blot. The results of this analysis are shown in Figure 4B and C. We found that NUFIP is present on the template ( Figure 4B , lane 2), but not on control empty beads (not shown), and remained bound after ATP or NTPs were added ( Figure 4B , lanes 5 and 8, respectively). We also investigated the effect of adding a competitor (ct-) DNA or Sarcosyl to the preassembled PICs. Poly[dI-dC], used as a nonspecific competitor, sequesters free transcription factors and pol II to prevent them from binding to the promoter and reinitiating transcription (Hoopes et al., 1992; Goodrich, 1998, 2002) . Under these conditions, we still detected NUFIP stably associated with the template (Figure 4B , compare lane 9 with lanes 3 and 6). The anionic detergent Sarcosyl has been shown to inhibit selectively reassembly of PICs and reinitiation of transcription, but not elongation, when added shortly after the addition of initiating nucleotides Roeder, 1985, 1987; Szentirmay and Sawadogo, 1994) . Again, Sarcosyl treatment did not remove NUFIP that remained tightly bound at the template, presumably with the elongation complexes ( Figure 4B , lane 10 versus lanes 4 and 7). In the absence of nuclear extract, NUFIP by itself binds to DNA with a low affinity in a nonsequence-specific fashion (data not shown). As a Figure 4 NUFIP is a component of AdDMLP PICs and remains associated with elongation complexes. (A) Scheme to investigate association between NUFIP, TBP, TFIIH, and P-TEFb and template-bound transcription complexes at different stages. PICs were formed on AdDMLP-containing DNA template immobilized on magnetic beads. The washed PICs were divided into three aliquots: one was resuspended in transcription buffer only; the second portion was supplemented with ATP; and the third aliquot was supplemented with NTPs. After 1 min incubation at 301C, all three reactions were further divided into three sub-aliquots: competitor DNA poly[dI-dC] (ct-DNA) was added to one; and Sarcosyl (Sarc.) to another. The reactions were then incubated for a further 60 min at 301C. The unbound material was removed by extensive washing, and the protein complexes were eluted from beads, separated by SDS-PAGE, and analysed by Western blotting (panels B and C). (B) Stable appearance of NUFIP in the template-bound transcription complexes. The absence or presence of nucleotides in individual reactions is indicated below the lanes. As indicated above the lanes, some reactions contained competitor DNA (lanes 3, 6, and 9) or Sarcosyl (lanes 4, 7, and 10). Transcriptional activation by BRCA1/NUFIP/P-TEFb P Čabart et al control (see Figure 4D) , inclusion of the competitor poly[dI-dC] to the reactions resulted in an abolishment of the NUFIP binding to the promoter only when added before the PICs were formed ( Figure 4E , lanes 2, 5 and 8). However, when poly[dI-dC] was added at time 0 or þ 30 min, the template-bound NUFIP was detected in both open and elongating complexes ( Figure 4E , compare lane 7 with lane 6, and lane 10 with lane 9, respectively). In parallel to NUFIP, we also monitored three factors that are known to exhibit a differential appearance on the template through the transcription cycle. As shown in the upper panel of Figure 4C , TBP dissociates from the promoter upon addition of ATP ( Figure 4C , see lanes 2 and 3), in agreement with the data on SNF2/SWI2-related ATPase, which is analogous to yeast Mot-1 (Auble et al., 1994) . Further, consistent with the demonstration that TFIIH release occurs after the complex reaches minimally position þ 15 (Zawel et al., 1995; Dvir et al., 1997; Spangler et al., 2001) , we observed a decrease in the amount of subunit p89 of the TFIIH complex after the addition of NTPs ( Figure 4C , middle panel, compare lane 4 with lanes 2 and 3). In addition, Cyclin T1 remains associated with the template, in the phosphorylated form after the addition of ATP, and after the addition of NTPs ( Figure 4C , lower panel, compare lane 4 with lanes 2 and 3), as expected since P-TEFb remains associated with the template during HIV-1 5 0 -LTR transcription (Ping and Rana, 1999) . Similar data were obtained for association of cdk9 with the template (data not shown).
Taken together, these data suggest that NUFIP, similarly to P-TEFb, joins PICs and remains associated with the elongation complexes.
NUFIP co-immunoprecipitates with the P-TEFb complex
The above observations raise the question whether NUFIP associates with the pol II transcription factors other than BRCA1. Various components of the pol II transcription machinery were immunoprecipitated from HeLa cell nuclear extracts with antibodies coupled to protein A-sepharose beads. As shown in Figure 5A , NUFIP was found to be co-immunoprecipitated by antibodies against both subunits of P-TEFb factor, cdk9 ( Figure 5A , lanes 9 and 12) and Cyclin T1 ( Figure 5A , lane 14). No NUFIP was detected in immunocomplexes retained by anti-TFIIB, TFIIH, large subunit of pol II, TFIIE, TBP, cdk7, and cdk8 antibodies ( Figure 5A , lanes 2-8, 10 and 11, respectively). NUFIP also binds to RNA in a sequence nonspecific fashion (Bardoni et al., 1999 ; our unpublished results). The NUFIP-cdk9 complex is resistant to RNase A treatment ( Figure 5A , lane 13), indicating that RNA is not required for interaction between NUFIP and P-TEFb.
NUFIP interacts with the Cyclin T1
Using a GST pull-down assay, we tested interaction between NUFIP and cdk9, Cyclin T1 and Cyclin K, a cdk9 regulatory subunit of an alternative form of Transcriptional activation by BRCA1/NUFIP/P-TEFb P Čabart et al P-TEFb (Edwards et al., 1998) . Cdk9, Cyclin T1, Cyclin K, and NUFIP were produced in E. coli as GST-tagged proteins and immobilized on glutathione-agarose beads. Equimolar amounts of GST-cdk9, Cyclin T1, Cyclin K, or GST alone were mixed with in vitro-translated and radiolabeled NUFIP ( Figure 5C ). Consistent with the results of the Co-IP experiment,
35
S-labeled NUFIP was retained by the GST-Cyclin T1 resin ( Figure 5B, lane 3) . However, NUFIP bound weakly to both GST-cdk9 and GST-Cyclin K ( Figure 5B, lanes 2 and 4) , suggesting that NUFIP contacts with the Cyclin T1 are primarily responsible for interaction with P-TEFb. Ethidium bromide was added to preclude the possibility that DNA mediates interactions between these proteins. It is important to note that interaction between NUFIP and Cyclin T1 is resistant to high ionic strength (0.4 M KCl) and a high concentration of nonionic detergent Nonidet P-40 (0.5%), indicating a tight interaction between NUFIP and Cyclin T1. This interaction was confirmed in a reciprocal experiment in which 35 S-Cyclin T1 bound to GST-NUFIP as efficiently as to GST-cdk9, the natural partner of Cyclin T1 ( Figure 5B , see lanes 7 and 9). The relatively low recovery of Cyclin T1 is likely to be due to the stringent conditions (0.4 M KCl, 0.5% NP-40) used in these GST pull-down experiments.
Taken together, our Co-IP and GST pull-down data suggest that NUFIP can communicate with the general transcription machinery through its interaction with PTEFb.
Overexpressed NUFIP, BRCA1, and Cyclin T1 synergistically stimulate SV40 transcription in 293 cells
To determine whether the functional interaction of NUFIP and BRCA1 involves P-TEFb, a cotransfection assay with expression plasmids encoding for NUFIP, BRCA1, cdk9, and Cyclin T1 was carried out. In the light of the previous transfection experiment where 1 mg of pNUFIP-wt was minimally required for measurable reporter activation, we used this DNA concentration for transfections of constructs driving expression of NUFIP and all other proteins. Regardless of the protein(s) expressed, levels of pol III (7SK and VA1) transcripts were unchanged ( Figure 6B ) in agreement with previous transfection results, indicating that these genes are proper internal controls. In contrast, pol II transcription was most affected when NUFIP, BRCA1, and Cyclin T1 were overexpressed, showing a strong B57-fold synergistic coactivation of the SV40-b-gal reporter ( Figure 6A , cf. lanes 2 and 13). Overexpression of cdk9 at the same time, however, resulted in a dramatic inhibition of SV40 transcription ( Figure 6A, lane 14) , suggesting that an excess of this protein interferes with the BRCA1-NUFIP-Cyclin T1 functional interaction. Individually and in the combinations shown in lanes 3-12 ( Figure 6A) , NUFIP, BRCA1, cdk9, and Cyclin T1 potentiated SV40-b-gal activity only slightly. Since the cotransfection of 1 mg of cdk9 expression construct in the context of all remaining plasmids led to transcriptional inhibition, we sought to determine its dosedependent effect within the range 0-1 mg DNA. The degree of cdk9-mediated inhibition corresponded to the amount of cdk9 cotransfected ( Figure 6C, lanes 3-6) . The inhibition is specific for cotransfection of NUFIP and BRCA1 together because separately these proteins had no influence on cdk9/Cyclin T1-induced transcriptional activation ( Figure 6C , cf. lanes 10 and 11 with Transcriptional activation by BRCA1/NUFIP/P-TEFb P Čabart et al lane 9). This enhancement, although lower, is similar to the cdk9/Cyclin T1-induced stimulation of the CMV promoter in HeLa cells (Peng et al., 1998) .
We conclude that NUFIP activates pol II transcription in vivo in concert with BRCA1 and Cyclin T1 from P-TEFb.
NUFIP facilitates the ATP-dependent release of hyperphosphorylated pol II from open transcription complex
Our previous experiments showed physical interactions between NUFIP and P-TEFb and their positive effect on BRCA1-mediated pol II stimulation. P-TEFb is required for transcription elongation of many genes Price, 1992, 1995) , and is proposed to facilitate the transition from abortive to productive elongation by phosphorylating the CTD of the largest subunit of pol II (Marshall et al., 1996) . Since pol II is converted from the hypophosphorylated (IIA) form, which is characteristic for PICs, to the processive hyperphosphorylated (IIO) form through the transcription cycle (Cadena and Dahmus, 1987; Laybourn and Dahmus, 1990) , we asked whether NUFIP can affect phosphorylation of the polymerase. As shown in the scheme in Figure 7A , PICs were given 60 min to form on an immobilized template ( Figure 3C , IT) and washed PICs were supplemented with GST or GST-NUFIP, which is active in stimulating pol II transcription in vitro ( Figure 3B ). These PICs were incubated without NTP(s), with ATP, or with NTPs. Surprisingly, immunoblotting of the bound and released fractions ( Figure 7B , beads and sups, respectively) revealed efficient and selective ATP-dependent dissociation of pol IIO from GST-NUFIP-treated complexes ( Figure 7B , cf. lanes 6 and 7 with lane 5). In the absence of NTPs, however, increasing amounts of GST-NUFIP had no effect on the template-bound pol IIA ( Figure 7B,  lanes 3 and 4 versus lane 2) . Regardless of the recombinant protein added, the majority of pol II was found in the IIO form in the unbound fraction after transcription was initiated by adding NTPs ( Figure 7B,  lanes 8-10) . Thus, NUFIP might affect transcription by selective ATP-dependent destabilization of excessive or incorrectly positioned hyperphosphorylated pol II during the transition from closed to open transcription complex.
Discussion
In this study, we show that (i) BRCA1 forms a complex with ubiquitous nuclear protein NUFIP, and (ii) NUFIP selectively binds to the transcription factor PTEFb and this interaction is mediated via subunit Cyclin T1. To analyse the significance of protein-protein interaction between NUFIP, BRCA1, and P-TEFb in a Experimental design to test the effect of recombinant NUFIP on a template-bound pol II: PICs were assembled on beaded DMLP template. The purified PICs were supplemented with GST or GST-NUFIP and reactions were proceeded in the absence of nucleotides or in the presence of ATP or NTPs. At the end of the reaction, the supernatants and material eluted from beads were subjected to Western blot analysis using the anti-pol II antibody that recognizes both hypophosphorylated (IIA) and hyperphosphorylated (IIO) forms of large subunit of pol II (panel B). (B) Distribution of pol IIA and pol IIO forms in different transcription complexes treated with 100 ng of GST (lanes 2, 5, and 8) or 30 and 100 ng of GST-NUFIP (lanes 3, 6, 9 and 4, 7, 10, respectively). The upper panel (beads) shows template-bound pol II forms and the lower panel (sups) shows released pol IIO. Lane 1 shows the position of pol IIA in the nuclear extract (NE). Addition of NTPs to the reactions is indicated below the lanes Transcriptional activation by BRCA1/NUFIP/P-TEFb P Čabart et al physiological context, we used a transient transfection assay. First, NUFIP overexpression itself increases the activity of the pol II-transcribed SV40 promoter in both 293 and HeLa cells. Importantly, the activities of pol III and pol I promoters remain unaffected, indicating a specific role for NUFIP in the regulation of pol II transcription. Second, cotransfection of NUFIP and Cyclin T1 strongly stimulates BRCA1-dependent activation in 293 cells. This enhancement might be attributable to the presence of uncomplexed cdk9 in the cells being driven into active BRCA1-NUFIP-PTEFb complex by increasing the concentration of Cyclin T1. It is possible that such a complex might compete with or titrate out an inhibitor of P-TEFb. On the other hand, coexpression of cdk9 results in a dose-dependent abolishment of transactivation by these proteins, suggesting that an excessive or unfunctional complex is likely to be responsible for squelching or a toxic effect, respectively. If the two isoforms of cdk9 (Shore et al., 2003) do not have redundant functions, an alternative possibility that the overexpressed cdk9 (42) interferes with the activity of cdk9 (55) within BRCA1-NUFIP-PTEFb complex has to be considered. Since NUFIP interacts preferentially with Cyclin T1 and Cyclin K has a considerably shorter C-terminal domain, we assume that NUFIP binds the long C-terminal extension of CycT1. However, detailed mapping of NUFIP-CycT1 contacts is required to determine the architecture of NUFIP-P-TEFb complex. Given the existing information on the structure of NUFIP, it is relevant to ask about the potential function for zinc-finger domain. Although a molecular target remains to be identified, it is evident that the intact zinc-finger is indispensable for NUFIP-mediated pol II transcriptional upregulation. Since NUFIP alone was capable of activating the SV40 promoter in vivo, we analysed the role of NUFIP in a model cell-free pol II transcription system. The generation of the anti-NUFIP antibody, which is capable of debilitating AdML gene transcription when used to deplete transcription extract, allowed us to perform an add-back experiment with recombinant NUFIP proteins expressed in either bacterial or human cells. We found that restoration of in vitro transcription in such extract cannot be achieved by NUFIP alone but likely requires a complex of NUFIP and associated factors isolated from 293 cells expressing a tagged NUFIP. In contrast, addition of just recombinant NUFIP is sufficient to stimulate the transcription activity of undepleted extract. Moreover, this effect was observed on transcription that has been limited to the basal level using an AdML-based promoter that lacks upstream activator sequences, but does include an intact initiator, TATA box and BRE element. Thus, it seems reasonable to conclude that at least one innate function of NUFIP is to potentiate the gene expression at the level of activator-independent transcription. Based on subnuclear localization of NUFIP, its involvement in early steps after mRNA synthesis has also been proposed (Bardoni et al., 2003) .
Using the immobilized-AdML core promoter assay, we next attempted to determine the fate of NUFIP during the assembly of PICs and transition from initiation to elongation. We found that NUFIP assembles into PICs and most likely remains present in elongating complexes consistent with a possible role in elongation of transcription and interaction with PTEFb. For most of the genes, it is not yet clear how P-TEFb is recruited during transcription. The broad requirement for P-TEFb suggests that, in addition to gene-specific RNA-or DNA-bound activators (reviewed in Price, 2000) , a more 'universal' mechanism of P-TEFb recruitment is likely to operate. It will therefore be of great interest to determine whether NUFIP is generally involved in the recruitment of elongation factor PTEFb.
Eucaryotic cells contain two major forms of pol II, an unmodified or hypophosphorylated IIA form and heavily phosphorylated IIO form (Dahmus, 1981; Cadena and Dahmus, 1987) . In vitro, purified hypophosphorylated pol IIA can be efficiently assembled into functional PICs (Laybourn and Dahmus, 1990; Lu et al., 1991) . Pol II that is actively engaged in transcription is highly phosphorylated by multiple kinases both in vitro and in vivo (Cadena and Dahmus, 1987; Laybourn and Dahmus, 1990; Akoulitchev et al., 1995) . Within the large subunit of pol II, the reversible phosphorylation of CTD has been demonstrated to play an important role in the regulation of pol II transcription activity (Dahmus, 1994) . The CTD is a substrate also for the cdk9 subunit of P-TEFb, which preferentially phosphorylates a partially phosphorylated CTD (Marshall et al., 1996) . Importantly, P-TEFb can also prephosphorylate CTD while still present in PICs (Wada et al., 1998) and thus allows the polymerase to at least partially overcome the action of N-TEF. If therefore NUFIP, sequestered to pol II holoenzyme via BRCA1, is capable of recruiting P-TEFb, phosphorylation of both CTD and DSIF by cdk9 could modify the functional properties of pol II (Figure 8 ).
The efficiency of transcription is governed not only by the efficiency of PICs formation and elongation, but also by the efficiency and accuracy of open complex formation. Our findings indicate that exogenously added Figure 8 A model for NUFIP involvement in activation of pol II transcription. NUFIP may be involved in BRCA1-mediated bridging between P-TEFb and the pol II holoenzyme. BRCA1 is linked to the RNA helicase A (RHA) component of pol II holoenzyme, through its C-terminus. The N-terminal part of BRCA1 interacts with NUFIP, which then recruits P-TEFb via Cyclin T1. Cdk9, a kinase subunit of P-TEFb, then phosphorylates both the CTD of the large subunit of pol II and the DSIF subunit of N-TEF that results in an elongation enhancement Transcriptional activation by BRCA1/NUFIP/P-TEFb P Čabart et al NUFIP might exert an effect on transcriptional control by ATP-driven reorganization of the PIC. One possibility is that NUFIP uses ATP hydrolysis at activated promoters to induce a conformational change in a pol II-containing complex that specifically facilitates the disassembling of 'excessive' pol IIO during transition to open complex. A protein phosphatase specific for pol IIO (Chambers et al., 1995) likely dephosphorylates the pol II CTD during the elongation process. If this happens, DSIF and NELF may become reassociated with this pol II and thus cause its pausing. Therefore, it is also possible that functional NUFIP-P-TEFb interaction may prohibit DSIF/NELF from associating with pol IIA. Upon promoter clearance, such polymerase complexes may be resistant to the action of negative factors. Intriguingly, NELF also associates with BRCA1 via its NELF-B/COBRA1 subunit (Ye et al., 2001; Narita et al., 2003) . It is therefore possible that BRCA1 is involved, both directly and indirectly, in the interplay of positive and negative elongation factors. Moreover, COBRA1 regulates BRCA1 function in a chromatin decompression assay (Ye et al., 2001) . BRCA1-mediated unfolding is a critical step in transcriptional activation because it makes DNA near the promoter regions more accessible to the basal transcription machinery and pol II.
Further, it is important to consider the possibility that NUFIP may undergo differential post-translational modifications that confer NUFIP different activities depending on promoter context in which this protein is found. Since the expression profile of NUFIP remains constant through the cell cycle and several putative phosphorylation sites are present on NUFIP molecule (not shown), differential phosphorylation may play a role in the regulation of activity of NUFIP.
In conclusion, we suggest that the BRCA1-and PTEFb-interacting protein NUFIP is required for fulfilling one of the distinct BRCA1 functions in transcription. The next step will be to investigate the biological relevance of this finding. Of particular importance would be a possibility that it reflects a role for BRCA1 in transcription-coupled repair. Transcription activation could be a physiological function of BRCA1 but still be unrelated to its role in tumor suppression. However, the fact that cancer-associated mutations result in loss of transcriptional activation (Chapman and Verma, 1996; Monteiro et al., 1996) provided a genetic framework to link the transcriptional activation function of BRCA1 and presumably its complexes to the development of cancer.
Materials and methods
Yeast two-hybrid screen A 1.5 kb cDNA encoding the amino-terminal 511 residues of BRCA1 was inserted into the pAS1 expression vector. The resultant plasmid (pAS1/BRCA1 1.5) encodes a hybrid protein containing the DNA-binding domain of GAL4 fused to BRCA1 residues 1-511. pAS1/BRCA1 1.5 was used as 'bait' to screen a human B-lymphocyte cDNA library fused to the GAL4 transactivation domain (pSE1106) as previously described (Durfee et al., 1993) . Interacting clones were subcloned into pBSK (Stratagene, La Jolla, CA, USA) and sequenced.
Purification of GST fusion proteins
The 1.6 kb cDNA encoding NUFIP was cloned into pGEX-2T (Amersham Pharmacia Biotech.) to produce GST-NUFIP. GST-BRCA1(1-303) is a C-terminus deletion derivative from full-length BRCA1 clone (Chen et al., 1996) fused to GST tag at the N-terminus of the protein. The plasmids encoding GSTCyclin T1 and GST-Cyclin K have been described previously (Fujinaga et al., 1999; Edwards et al., 1998) . The construct for expression of GST-tagged cdk9 was kindly provided by Antonio Giordano. Recombinant GST and GST fusion proteins were expressed in E.coli cells and purified on glutathione-agarose (Sigma Chemical Co.) as described previously (Cabart and Murphy, 2001 ). GST and GST-NUFIP were eluted from beads using 50 mM reduced glutathione (Sigma) in buffer A (20 mM Tris-HCl at pH 8.0, 100 mM KCl, 10% glycerol, 0.5 mM EDTA, 1 mM DTT, and 0.5 mM phenylmethylsulfonyl fluoride (PMSF)) and dialysed against buffer A. The amount of bound and eluted protein was estimated by comparison with a bovine serum albumin (BSA) standard in Coomassie blue-stained SDS-polyacrylamide gels.
Antibodies
Purified GST-NUFIP was used to generate the mouse polyclonal antibody anti-NUFIP. The antiserum was first depleted of anti-GST antibodies using a GST-agarose column and then purified on an affinity column (Affi-gel 10, Bio-Rad) coupled to GST-NUFIP. The Santa Cruz Biotechnology products, anti-cdk7, sc-529; anti-p89, sc-293; anti-p62, sc-292 (subunits of TFIIH); anti-a, sc-237; anti-b, sc-238 (subunits of TFIIF); anti-TFIIB, sc-274; anti-TBP, sc-273; anti-cdk8, sc-5612; anti-cdk9, sc-7331; anti-Cyclin T1, sc-10750; and antipol II, sc-9001 (large subunit) antibodies were purchased from Autogen Bioclear. Anti-BRCA1 antibody (sc-6954) is also a product of Santa Cruz Biotech. Monoclonal anti-HA tag antibody (clone 12CA5) was obtained from Roche Diagnostics.
Cell cultures and preparation of nuclear extracts
Human bladder carcinoma T24, cervical carcinoma HeLa, and embryonic kidney 293 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum at 371C in a 5% CO 2 atmosphere. Nuclear extracts were prepared from 293 and HeLa cells as described previously (Dignam et al., 1983) .
Western blotting
To test the specificity of anti-NUFIP antibody, full-length recombinant NUFIP was produced using a TnT-coupled transcription-translation system (Promega). pcDNA3.1 (Invitrogen) was used as a negative control. In parallel, T24 cells were boiled in urea-SDS cracking buffer (Kaelin et al., 1991) and loaded along with the rabbit reticulocyte lysate reactions onto an SDS-10% polyacrylamide gel. After electrophoresis, the proteins were transblotted onto polyvinylidene fluoride membrane (Millipore) and immunodetection was performed by enhanced chemiluminiscence (ECL) system (Amersham Biosciences) as recommended by the manufacturers.
Co-immunoprecipitation
HeLa nuclear extract (500 mg) was incubated at 41C for 3 h with 15 ml of protein A-sepharose beads covalently linked to the equivalent amounts of immunoglobulin G. Samples were then pelleted, supernatants removed, and beads washed five times with 500 ml of buffer (25 mM Tris-HCl, pH 7.9, 100 mM KCl, 12 mM MgCl 2, 10% glycerol, 0.5 mM EDTA, 1 mM DTT, 0.5 mM PMSF, and 0.05% NP-40). In the case of Co-IP by anti-cdk9, the immunocomplexes were either directly used for analysis or subjected to digestion with RNase A (40 mg/ml) at 301C for 10 min and beads were washed once more. Material that remained bound on the beads was then analysed by Western blotting.
Purification of HA-tagged proteins
The plasmid pcDNA3-5 0 -HA-BRCA1 expressing BRCA1 with the HA tag fused to the amino terminus (Scully et al., 1997b) was a kind gift of Jeffrey Parvin. The plasmid encoding HA-NUFIP was derived from construct pBSK-NUFIP by PCR amplification of the NUFIP coding region and placing into pHM6 (Roche) using KpnI and EcoRI sites. The preparation of 293 cell lines that express HA-tagged BRCA1 and NUFIP was as described (Scully et al., 1997a) . The recombinant proteins and associated protein complexes were purified from transfected cells essentially as described (Scully et al., 1997a) except that the immunoprecipitated proteins were eluted from the anti-HA immunoaffinity support by incubation with 0.5 mg/ml HA peptide (Roche). As a control, the eluate from cells lacking HA-tagged protein was prepared. The amount of recovered protein was analysed by immunoblotting and probing with respective antibody. When required, eluates were concentrated in Microsep centrifugal concentrators (Flowgen).
Transfections, S1 assay, and b-galactosidase reporter gene assay
Reporter plasmid pSV40-b-gal contains the coding sequences for bacterial b-galactosidase downstream of the simian virus (SV) 40 promoter. Reporter pVA1 has been described previously (Rohan and Ketner, 1987) . The O þ P þ construct (Murphy et al., 1992) was used as the 7SK reporter. Protein expression was driven by the CMV promoter. The plasmid encoding NUFIP (pNUFIP-wt) was derived from construct pBSK-NUFIP by PCR amplification of the NUFIP coding region and placing into pcDNA3.1 using BamHI and XhoI sites. In the pNUFIP-Zn À construct, the wild-type histidine codon CAT between 586 and 588 was mutated to GGT, and thus a new amino-acid codon for glycine at 196 was introduced. In addition, a second glycine at amino-acid position 199 was generated by the single nucleotide substitution T to G at 613. The plasmids coding for BRCA1 (pcDNA3-BRCA1) and Cyclin T1 (pcDNA3-Cyclin T1) have been described previously (Zheng et al., 2001; Peng et al., 1998) . The plasmid for cdk9 expression (pCEP4-cdk9) was a kind gift of Bassel Sawaya.
In all experiments, 293 cells were transiently transfected with 1 mg of pSV40-b-gal along with 0.25 mg of pVA1 and 2.5 mg of O þ P þ construct using LipofectAMINE (Invitrogen) according to the manufacturer's instructions. For the titration experiment ( Figure 2B ), the indicated concentrations of pNUFIP-wt or pNUFIP-Zn À were cotransfected. For the experiment shown in Figure 6 , 1 mg of each pNUFIP-wt, pcDNA3-BRCA1, and pcDNA3-Cyclin T1 and appropriate amounts of pCEP4-cdk9 were cotransfected as indicated. All reactions were balanced to contain the same amount of total DNA by the addition of pcDNA3.1.
For simultaneous preparation of RNA and protein, cells were harvested 48 h after transfection. Total RNA was isolated using the TRI Reagent (Sigma) and then analysed by S1 assay (Murphy, 1997) . The sequences of S1 oligonucleotides for VA1 and 7SK were described previously (Murphy, 1997) . S1 nuclease digestion products were fractionated on polyacrylamide gels containing 8 M urea. Quantitation was performed using a Molecular Dynamics PhosphorImager. Proteins were extracted into 0.25 M Tris-HCl at pH 8.0 by three freeze/thaw cycles using solid CO 2 /ethanol. The b-galactosidase activity of the soluble protein fraction was measured using chlorophenol red-b-D-galactopyranoside (Roche Diagnostics) as substrate and normalized to the protein concentration determined by the method of Bradford (Bio-Rad).
In vitro transcription
Transcription reactions were carried out as described by Parvin et al. (1994) . Two AdML promoter-derived G-less cassette transcription templates were used, pML(C 2 AT) (Sawadogo and Roeder, 1985) and pDMLP(200) (Buratowski et al., 1988) , which produce 400-and 210-nt G-less RNAs, respectively. The transcription reaction mixtures (50 ml) contained 0.2 mg of pML(C 2 AT) and 10 ml of untreated or immunodepleted HeLa nuclear extract (diluted 1 : 1 relative to the starting extract). Where indicated, depleted extract was supplemented with various amounts of HA-tagged protein(s) or control eluate. NUFIP-mediated activation of basal transcription was analysed using 0.5 mg of pDMLP(200) and 293 nuclear extract in a total volume of 25 ml. Where indicated, the nuclear extract was preincubated with various concentrations of GST-NUFIP or GST. Following 1-h incubation at 301C, transcripts were subjected to electrophoresis on 8 M urea/6% acrylamide gels. Gels were dried and used to expose either autoradiographic film or phosphorimager screen for quantitation.
For immunodepletions, 100 ml of HeLa nuclear extract (10 mg/ml) was mixed with 100 ml of protein A-sepharose beads carrying the antibody of interest and incubated overnight at 41C with rotation. The beads were then pelleted and the supernatant was used directly for transcription as described above.
Purification of PICs
A 263 bp fragment containing the core promoter sequence upstream from 200 bp G-less cassette between À53 and þ 210 relative to the AdML gene transcription start site was generated from pDMLP(200) by PCR and simultaneously biotinylated at the 3 0 -end. The fragment was immobilized on Dynabeads M-280 Streptavidin (Dynal) by incubation for 20 min, and PICs were formed by incubating the immobilized DMLP template (150 ng) in a volume of 30 ml containing 50 mg of HeLa nuclear extract, 8 mM MgCl 2 , and 1 mg of sonicated herring sperm DNA (Sigma) for 1 h at 301C with rocking. PICs were washed with 200 ml of transcription buffer TB (10 mM Tris-HCl, pH 7.9, 20 mM HEPES, pH 7.9, 50 mM KCl, 8 mM MgCl 2 , 5mM (NH 4 ) 2 SO 4 , 2% PEG 8000, 10% glycerol, 0.05 mM EDTA, 1 mM DTT, 0.5 mM PMSF, and 50 mg of BSA per ml) containing 0.05% NP-40.
Analysis of proteins on immobilized template
The purified PICs were resuspended in 25 ml of TB containing 10 U of ribonuclease inhibitor. As indicated in individual experiments, reactions were supplemented with 1 mM ATP or 1 mM of each ATP, CTP, and UTP (NTPs). When appropriate, 1.5 mg of poly [dI-dC] or Sarcosyl (final concentration Transcriptional activation by BRCA1/NUFIP/P-TEFb P Čabart et al 0.015%) was added to the reactions containing PICs and the mixtures incubated for an additional 1 h at 301C. In the part of experiment shown in Figure 4E , 1.5 mg of poly [dI-dC] was mixed simultaneously with the template and nuclear extract. After washing twice with TB buffer plus 0.05% NP-40, the bound complexes were eluted from beads with 5 M urea in 50 mM Tris-HCl, pH 7.9, resolved in SDS-10% PAGE and analysed by Western blotting using antibodies to NUFIP, TBP, p89 (subunit of TFIIH), and Cyclin T1 (subunit of PTEFb).
Analysis of NUFIP-treated pol II transcription complexes
For the experiment in Figure 7 , reaction mixtures were prepared as described above, and GST-NUFIP or GST was added and reactions continued in the presence or absence of nucleotides for 1 h at 301C. The solution phases were saved and analysed along with the complexes eluted from washed beads by Western blotting. The anti-pol II antibody (sc-9001) used recognizes both hypo-and hyperphosphorylated forms of large subunit of pol II.
GST pull-down assay
The unlabeled full-length NUFIP and 35 S-Met-labeled NUFIP and Cyclin T1 were produced by in vitro transcriptiontranslation in rabbit reticulocyte lysate. All protein-protein binding reactions were carried out at 41C for 2 h. Equal amounts of GST-BRCA1(1-303) and GST proteins bound to glutathione beads were rotated with unlabeled NUFIP in the binding buffer (20 mM HEPES, pH 7.9, 10% glycerol, 0.5 mM MgCl 2 , 0.5% NP-40, 0.2 mM EDTA, and 0.4 mg ethidium bromide per ml) containing 100 mM KCl. As indicated in Figure 5B , glutathione-agarose-immobilized GST-cdk9, GSTCyclin T1, GST-Cyclin K, GST-NUFIP, and GST proteins were incubated with 35 S-labeled proteins in the binding buffer containing 400 mM KCl. The beads were washed five times with the corresponding binding buffer and the retained unlabeled NUFIP was analysed by Western blotting. Radiolabeled proteins were analysed by SDS-10% PAGE and autoradiography.
